Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | BRAF V600E |
Therapy | Tovorafenib |
Indication/Tumor Type | low grade glioma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E | low grade glioma | predicted - sensitive | Tovorafenib | Phase II | Actionable | In a Phase II trial (FIREFLY-1), Tovorafenib (MLN2480) treatment was well-tolerated and resulted in an overall response rate of 64% (44/69, 3 complete responses, 41 partial responses (10 unconfirmed)) and a clinical benefit rate of 91% in pediatric patients with low-grade glioma harboring BRAF fusions (n=64) or BRAF V600E (n=13) (J Clin Oncol 41, 2023 (suppl 16; abstr 10004); NCT04775485). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study | Full reference... |